2.要約四半期連結財務諸表及び主な注記

(1)要約四半期連結財政状態計算書

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2026年3月31日)

 

当第1四半期連結会計期間

(2026年6月30日)

資産

 

 

 

 

 

流動資産

 

 

 

 

 

現金及び現金同等物

 

 

76,592

 

72,699

営業債権及びその他の債権

 

 

46,157

 

50,567

棚卸資産

 

 

51,595

 

51,168

その他の金融資産

 

 

2,414

 

2,425

その他の流動資産

 

 

6,326

 

6,313

流動資産合計

 

 

183,086

 

183,175

非流動資産

 

 

 

 

 

有形固定資産

 

 

34,954

 

35,216

無形資産

 

 

48,242

 

49,970

使用権資産

 

 

2,588

 

2,578

その他の金融資産

 

 

67,356

 

64,143

繰延税金資産

 

 

6,957

 

6,957

その他の非流動資産

 

 

3,172

 

3,111

非流動資産合計

 

 

163,272

 

161,978

資産合計

 

 

346,359

 

345,153

 

 

 

 

 

 

 

 

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2026年3月31日)

 

当第1四半期連結会計期間

(2026年6月30日)

負債及び資本

 

 

 

 

 

負債

 

 

 

 

 

流動負債

 

 

 

 

 

営業債務及びその他の債務

 

 

26,132

 

24,956

その他の金融負債

 

 

273

 

246

リース負債

 

 

913

 

1,452

未払法人所得税

 

 

6,979

 

2,850

その他の流動負債

 

 

7,806

 

9,837

流動負債合計

 

 

42,105

 

39,343

非流動負債

 

 

 

 

 

その他の金融負債

 

 

235

 

235

リース負債

 

 

1,654

 

1,106

退職給付に係る負債

 

 

4,557

 

4,158

繰延税金負債

 

 

5,875

 

4,519

その他の非流動負債

 

 

59

 

59

非流動負債合計

 

 

12,382

 

10,079

負債合計

 

 

54,488

 

49,423

資本

 

 

 

 

 

資本金

 

 

5,174

 

5,174

資本剰余金

 

 

4,547

 

4,564

利益剰余金

 

 

246,691

 

252,622

自己株式

 

 

△2,440

 

△2,440

その他の資本の構成要素

 

 

37,578

 

35,490

親会社の所有者に帰属する持分合計

 

 

291,551

 

295,411

非支配持分

 

 

319

 

318

資本合計

 

 

291,871

 

295,730

負債及び資本合計

 

 

346,359

 

345,153

 

E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2026-04-012026-06-30Q12027-03-312025-04-012025-06-302026-03-311falsefalsefalse451602026-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-04-012025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602026-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-03-31jpigp_cor:ShareCapitalIFRSMember451602026-03-31jpigp_cor:CapitalSurplusIFRSMember451602026-03-31jpigp_cor:RetainedEarningsIFRSMember451602026-03-31jpigp_cor:TreasurySharesIFRSMember451602026-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31451602026-03-31451602025-06-30451602026-04-012026-06-30451602026-06-30451602026-08-06451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-06-30451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602026-04-012026-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-04-012026-06-30jpigp_cor:ShareCapitalIFRSMember451602026-04-012026-06-30jpigp_cor:CapitalSurplusIFRSMember451602026-04-012026-06-30jpigp_cor:RetainedEarningsIFRSMember451602026-04-012026-06-30jpigp_cor:TreasurySharesIFRSMember451602026-04-012026-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-04-012026-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-04-012026-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-04-012026-06-30jpigp_cor:NonControllingInterestsIFRSMember451602026-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-06-30jpigp_cor:ShareCapitalIFRSMember451602026-06-30jpigp_cor:CapitalSurplusIFRSMember451602026-06-30jpigp_cor:RetainedEarningsIFRSMember451602026-06-30jpigp_cor:TreasurySharesIFRSMember451602026-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-06-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602025-04-012025-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-06-30jpcrp_cor:ReconcilingItemsMember451602026-04-012026-06-30jpcrp_cor:ReportableSegmentsMember451602026-04-012026-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602026-04-012026-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602026-04-012026-06-30jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure